Welcome to our dedicated page for EIGR news (Ticker: EIGR), a resource for investors and traders seeking the latest updates and insights on EIGR stock.
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, research milestones, and strategic initiatives.
Our curated collection features official press releases, regulatory filings, and clinical trial progress reports. Key areas of coverage include therapeutic pipeline updates, partnership announcements, and details regarding the company’s ongoing restructuring process under Chapter 11 protection.
Users will find essential information about Eiger’s asset management strategies, including potential licensing agreements and court-supervised sales of clinical-stage therapies. The repository maintains neutral reporting on financial repositioning efforts while highlighting scientific advancements in hepatitis delta virus (HDV) and other rare disease research programs.
Bookmark this page for streamlined access to verified updates about EIGR’s operational changes and research developments. Check regularly for new information about therapeutic candidate evaluations, strategic partnerships, and restructuring milestones that shape the company’s trajectory in biopharmaceutical innovation.
Eiger BioPharmaceuticals (Nasdaq: EIGR) will host a conference call on May 5, 2022, at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update. The company specializes in developing therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes two first-in-class therapies currently in Phase 3 trials, with all five rare disease programs having received FDA breakthrough therapy designation. The webcast will be available for replay for at least 90 days.
Eiger BioPharmaceuticals appoints Chris Kurtz as Chief Technical Officer and Sarah Mathieson as Senior Vice President, Corporate Affairs. These appointments come as the company advances its late-stage pipeline, particularly for Hepatitis Delta Virus therapies. Eiger anticipates topline data from its Phase 3 D-LIVR study by the end of 2022, along with positive data from the TOGETHER study for COVID-19.
Kurtz brings 30 years of experience in technical operations, while Mathieson has 25 years in corporate communications.
Eiger BioPharmaceuticals (Nasdaq:EIGR) announced significant results from the Phase 3 TOGETHER study using Peginterferon Lambda. The trial, featuring 1,936 COVID-19 outpatient participants, showed Lambda reduced the risk of hospitalizations or ER visits by 50% and COVID-19-related deaths by 60%. The treatment demonstrated a 99.91% probability of superiority against placebo across multiple variants, including omicron. Eiger plans to submit data for Emergency Use Authorization (EUA) to the FDA.
Eiger BioPharmaceuticals (Nasdaq:EIGR) will host a conference call on March 17, 2022, at 5:30 AM Pacific / 8:30 AM Eastern to discuss results from the Phase 3 TOGETHER study of Peginterferon Lambda for COVID-19. The company focuses on innovative therapies for Hepatitis Delta Virus (HDV) and other serious diseases, with multiple programs granted FDA Breakthrough Therapy Designation. Investors can access the live call or replay via the company's website.
Eiger BioPharmaceuticals (Nasdaq:EIGR) reported its fourth quarter and full year 2021 financial results. The company holds a strong cash position of approximately $106 million as of December 31, 2021. Key developments include the Phase 3 TOGETHER study for COVID-19 and the D-LIVR study for Hepatitis Delta Virus, with topline data expected in March and by the end of 2022, respectively. Revenue from Zokinvy was $3.4 million in Q4, with full-year sales at $12.1 million. Net losses were $21.8 million in Q4, compared to $18.8 million in the same period in 2020.
Eiger BioPharmaceuticals (Nasdaq:EIGR) is set to host a conference call on March 10, 2022, at 4:30 PM ET to discuss its fourth quarter and full year 2021 financial results. The call aims to provide a comprehensive business update for investors. Eiger is focused on developing innovative therapies targeting Hepatitis Delta Virus (HDV) and other rare diseases. Notably, all five of its rare disease programs have received FDA Breakthrough Therapy Designation, signifying strong progress in its clinical pipeline.
Eiger BioPharmaceuticals (Nasdaq:EIGR) provided a comprehensive outlook for 2022, focusing on its pipeline programs. Key highlights include the anticipated topline data from the pivotal D-LIVR Phase 3 study for Lonafarnib, expected by year-end. This trial represents the largest conducted in Hepatitis Delta Virus (HDV). Additionally, the company is enrolling patients in the LIMT-2 trial for Peginterferon Lambda. Eiger reported approximately $106 million in cash and equivalents at the start of 2022, emphasizing its commitment to developing innovative therapies for HDV and other rare diseases.
Eiger BioPharmaceuticals, based in Palo Alto, announced that CEO David Cory will deliver a corporate update at the H.C. Wainwright BioConnect 2022 Virtual Conference. This presentation will be pre-recorded and accessible on their website starting at 7:00 AM ET on January 10, 2022, for 90 days. Eiger is focused on developing therapies for Hepatitis Delta Virus (HDV) and other rare diseases, with five programs having received FDA Breakthrough Therapy Designation. The company aims to innovate treatments that directly target viral replication processes.
Eiger BioPharmaceuticals (Nasdaq:EIGR) has announced the enrollment of the first patient in its Phase 3 LIMT-2 study, examining Peginterferon Lambda for treating chronic Hepatitis Delta Virus (HDV). The study aims to enroll 150 patients across 50 sites in 13 countries, comparing a treatment group to a no-treatment group followed by treatment. The primary goal is to assess the Durable Virologic Response (DVR) at 24 weeks post-treatment. Eiger is pursuing regulatory approval, with Peginterferon Lambda already receiving Orphan Designation and Fast Track status from the FDA.
Eiger BioPharmaceuticals (Nasdaq:EIGR) announced that the Data Safety Monitoring Board (DSMB) has recommended the continuation of the Phase 3 TOGETHER study, following a second interim futility analysis involving 1,003 patients. The study aims to evaluate Peginterferon Lambda's effectiveness in high-risk COVID-19 patients, with a primary endpoint focused on emergency visits, hospitalizations, and deaths. The trial is set to enroll up to 1,600 patients across 12 sites in Brazil, highlighting the urgent need for new COVID-19 treatments.
